🔴 Moleculin Biotech is trading 5.75% down as the cause remains unclear

Moleculin Biotech is trading at $8.22, down 5.75%, with no clear cause identified.

• On October 30, Moleculin Biotech announced dosing is complete in Part A of its pivotal MIRACLE trial; comprehensive data are expected in Q1 2027.
• The announcement reports trial progress but does not explain the share-price decline.
• No reliable report linked the drop to a company-specific event or broader market move; available biotech coverage described the sector as broadly steady.